৳ 833.33/unit
Pack: ৳ 24,999.90
৳ 833.33/unit
Pack: ৳ 24,999.90
At a glance
Niraparib is a PARP inhibitor used for maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. It inhibits PARP enzymes to cause DNA damage and cell death.
Indications
- Maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer (in complete or partial response to platinum-based chemotherapy)
Pharmacology
Niraparib inhibits PARP-1 and PARP-2 enzymes to prevent DNA repair, resulting in DNA damage and apoptosis. It increases cytotoxicity in tumor cell lines with or without BRCA1/2 deficiencies.
Dosage
Adult Dose (Oral):
- 300 mg (three 100 mg capsules) once daily
- Continue until disease progression or unacceptable toxicity
- Start within 8 weeks of platinum-based chemotherapy
Side effects
Common Side Effects (>10%):
- Nausea (74%)
- Thrombocytopenia (61%)
- Fatigue/asthenia (57%)
- Anemia (50%)
- Constipation (40%)
- Vomiting (34%)
- Abdominal pain/distention (33%)
- Neutropenia (30%)
- Insomnia (27%)
- Headache (26%)
- Hypertension (20%)
- Diarrhea (20%)
Serious: MDS/AML, bone marrow suppression, hypertensive crisis
Use in pregnancy
Use in Pregnancy: Niraparib is highly unsafe during pregnancy; definite evidence of severe fetal harm. Do not use.
Pregnancy Category: D — always consult a doctor before taking during pregnancy.
Precautions & warnings
- Discontinue if MDS/AML is confirmed
- May cause bone marrow suppression; monitor CBC regularly (weekly first month, monthly next 11 months)
- Hypertension and hypertensive crisis may occur; monitor BP monthly for first year
- Can cause fetal harm; use effective contraception
Overdose effects
No specific treatment for overdose; symptomatic supportive measures.
Storage conditions
Store in a cool and dry place; do not store above 30°C; do not use if exposed to temperatures >40°C.